Expression and Prognosis Analysis of JMJD5 in Human Cancers

Abstract JumonjiC (JmjC) domain-containing protein 5 (JMJD5) plays an important role in cancer metabolism. However, the prognostic value of JMJD5 in most human cancers is still unknown. In this study, we aim to investigate the expression and prognostic value of JMJD5, immune cells infiltration, and the correlations among them. We found: The expression of JMJD5 was significantly lower in human breast carcinoma (BRCA), cholangiocarcinoma (CHOL), liver hepatocellular carcinoma (LIHC) and lung cancer (LUC) but higher in prostate adenocarcinoma (PRAD) and stomach adenocarcinoma (STAD) comparing to their respective normal tissues by online Tumor Immune Estimation Resource (TIMER) and immunohistochemistry (IHC) of tissue microarray sections (TMAs) respectively. And high expression of JMJD5 has better prognosis only in BRCA, LIHC, LUC but the opposite effect in STAD by the Kaplan-Meier Plotter databases analyses. Further analysis revealed JMJD5 expression is significant correlation with the abundance of six immune cells infiltration in above four cancers by TIMER, and evaluated the prognostic value by the combination of JMJD5 expression with either B cells or macrophages tumor infiltration by the COX proportional hazards model. Both the BRCA or lung adenocarcinoma (LUAD) patients with abundance of B cell and the STAD patients with low level of macrophage have a better cumulative survival by TIMER. In conclusion, we provided novel evidence of JMJD5 as an essential prognostic biomarker in cancers through analyses the correction of the JMJD5 expression, tumor-infiltrating B cells and macrophages and prognostic value. This study offers new perspectives therapeutic target in BRCA, LUAD and STAD.